---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-139402"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:50:10.948331+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Soleno completes PWS trial enrollment, gets $10M; Q1 net loss $8.4M

## Summary
- Enrollment completed in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome; top-line data expected Q3 2023.
- Received $10M from closing of December 2022 securities purchase agreement with Nantahala, Abingworth, Vivo Capital; warrants for 22.6M shares issued.
- Cash and equivalents $7.9M at March 31, 2023; plus $10M received, expected to fund through top-line data.
- Net loss $8.4M ($0.88 per share) vs $5.7M ($1.07) in Q1 2022; R&D expenses $5.3M vs $4.0M.

## SEC filing metadata
- accession: 0001193125-23-139402
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312523139402/0001193125-23-139402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312523139402/d421828d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-139402
- JSON: https://secwatch.observer/filing/0001193125-23-139402.json
- Plain text: https://secwatch.observer/filing/0001193125-23-139402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.